School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Celldex Therapeutics Inc CLDX

Healthcare · Biotechnology

$29.89last close 2026-10-09 · market cap $2.35B · delayed data

Trailing returns

1M-22.92%
3M-23.32%
6M-11.09%
1Y+8.53%
5Y-44.81%

Basis: Adjusted daily closes.

What it does

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.

Open CLDX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies